Tirzepatide is FDA-approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition (such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea)
Most manufacturers recommend avoiding semaglutide and tirzepatide during breastfeeding as a precautionary measure, since adequate nutrition is essential for milk supply and infant health
Very little, like most IV drips, its fairly quick with little downtime
Human studies have reported improved healing of diabetic foot ulcers and distal radius fractures, while animal studies suggest TP508 may stimulate bone regeneration in critical-size defects
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the BrainAdipocyte Axis
Diet-induced obesity is associated with an impaired NK cell function and an increased colon cancer incidence